Ocugen Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
OCGN Nasdaq 8731 https://ocugen.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ocugen Inc

Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy - May 15th, 2024 10:30 am
Ocugen Inc (OCGN) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances Amid ... - May 15th, 2024 7:02 am
Q1 2024 Ocugen Inc Earnings Call - May 15th, 2024 5:12 am
Ocugen Provides Business Update with First Quarter 2024 Financial Results - May 14th, 2024 12:00 pm
Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock - May 10th, 2024 8:05 pm
Ocugen to Present at May 2024 Investor Conferences - May 10th, 2024 11:45 am
Millionaire Blueprint: 3 Stocks Under $5 With Massive Growth Potential by 2028 - May 8th, 2024 10:00 am
Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results - May 3rd, 2024 11:30 am
Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress - May 2nd, 2024 11:15 am
Can Ocugen Stock Keep Churning Higher? - Apr 29th, 2024 12:30 pm
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024 - Apr 29th, 2024 10:45 am
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards? - Apr 26th, 2024 4:35 pm
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting - Apr 26th, 2024 1:05 pm
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting - Apr 26th, 2024 10:30 am
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy - Apr 19th, 2024 11:13 am
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets - Apr 12th, 2024 11:30 am
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication - Apr 10th, 2024 11:02 am
Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study - Apr 8th, 2024 4:13 pm
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication - Apr 8th, 2024 10:30 am
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy - Apr 5th, 2024 11:02 am